Early Detection Of
Ovarian Cancer Is Critical
Ovarian cancer is the deadliest gynecological cancer. Ovarian cancer is often diagnosed too late as three out of four ovarian cancer patients are diagnosed with advanced disease. Early intervention can significantly improve survival rates and is crucial for women who are known to be at higher risk for the disease. ClearNote Health has developed the Avantect Ovarian Cancer Test for women with high risk for ovarian cancer who carry genetic predispositions such as BRCA1, BRCA2 mutations or have a first-degree family member with ovarian cancer.
Ovarian cancer is the deadliest gynecological cancer and the fifth leading cause of cancer-related deaths among women.
leading cause of cancer-related death among women
Ovarian cancer diagnosed at its earliest stage can improve survival
Until now, limited early detection technologies for ovarian cancer have prevented patients from seeking treatment in early stages when more effective therapies are still possible. The stage of ovarian cancer at diagnosis has a significant impact on survival.
Addressing an Unmet Medical Need
Prioritizing high-risk patients
The Avantect Ovarian Cancer Test is a simple DNA-based blood test is designed to make earlier diagnosis possible for patients at high risk for ovarian cancer. It is therefore essential to identify patients at high risk for ovarian cancer who would benefit from testing.
